Developer docs
API playgroundTry for free, no card

Search company profiles

BioXcel Therapeutics

Full company profile

uuid0000ose

Namestring
BioXcel Therapeutics
Legal namestring
BioXcel Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

BioXcel Therapeutics is a clinical-stage biopharmaceutical company that applies its proprietary NovareAI platform — a composite of machine learning and big data analytics — to identify new therapeutic indications for existing approved drugs and clinically evaluated candidates, focusing on neuroscience and immuno-oncology. The company's lead commercial asset is IGALMI (BXCL501), a proprietary sublingual film formulation of dexmedetomidine that received FDA approval in April 2022 for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults, distributed as a prescription pharmaceutical through healthcare providers under direct supervision.

The pipeline is built around BXCL501 extensions into adjacent indications (at-home use of IGALMI under FDA review with a November 14, 2026 decision target, agitation in Alzheimer's dementia with Breakthrough Therapy designation, opioid withdrawal with positive Phase 2 data, and Department of War-funded acute stress trials) plus BXCL701, an oral innate immune activator housed in the OnkosXcel Therapeutics subsidiary for aggressive cancers including metastatic castration-resistant prostate cancer and pancreatic cancer. The company also lists early-stage candidates BXCL502 (chronic dementia agitation) and BXCL503 (dementia apathy).

BioXcel generates revenue solely from IGALMI product sales, which declined sharply from $2.266 million in FY2024 to $0.642 million in FY2025 as the company pivoted resources toward an at-home launch and FDA submission. The business model combines product commercialization with repeated dilutive registered direct equity offerings; capital has also been raised through a $260 million strategic financing agreement with Oaktree Capital Management and Qatar Investment Authority. The company has engaged MTS Health Partners to explore strategic options including a potential sale, merger, collaboration, or licensing for the IGALMI franchise. BioXcel is headquartered in New Haven, Connecticut, trades on NASDAQ under ticker BTAI, and operates as a Delaware-incorporated C-corporation.

Short descriptiontext

BioXcel Therapeutics is a clinical-stage biopharmaceutical company using its proprietary NovareAI platform to re-innovate existing drugs, commercializing IGALMI for acute agitation in schizophrenia/bipolar disorder and developing pipeline candidates BXCL501 (multiple neuroscience indications) and BXCL701 (immuno-oncology).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI-driven drug discovery, neuroscience therapeutics, immuno-oncology treatments, sublingual pharmaceutical films, clinical-stage biopharmaceutical
Industry5 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage biopharmaceutical (neuroscience and immuno-oncology)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1IGALMI Product Sales
TypeOne Time License
Description

BioXcel Therapeutics generates revenue from commercial sales of IGALMI (dexmedetomidine sublingual film), FDA-approved for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company reports declining revenue as focus shifts to at-home launch preparations.

biospace.com
2Strategic Financing
TypeTransaction Fee
Description

The company has raised capital through registered direct offerings of common stock and warrants, and strategic financing agreements with institutional investors including credit facilities and revenue interest financing.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1IGALMI
Description

FDA-approved dexmedetomidine sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

bioxceltherapeutics.com
+1 more record
Core offering1 text field

BioXcel Therapeutics develops and commercializes AI-enabled pharmaceutical products in neuroscience and immuno-oncology. Its commercial product is IGALMI, a sublingual dexmedetomidine film FDA-approved for acute agitation in schizophrenia and bipolar I/II disorder. The company also develops pipeline candidates including BXCL501 (additional agitation, opioid withdrawal, and acute stress indications), BXCL701 (immuno-oncology), BXCL502, and BXCL503, leveraging its proprietary NovareAI platform for drug re-innovation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 3 SERENITY At-Home trial met primary safety objective; BXCL501 reduced agitation compared to placebo across all baseline severity levels
+2 more records
Product overview1 text field

BioXcel Therapeutics is a clinical-stage biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience and immuno-oncology. The company's commercial product is IGALMI™ (dexmedetomidine sublingual film), FDA-approved for acute treatment of agitation associated with schizophrenia or bipolar disorder. Its pipeline includes BXCL501, the same formulation in development for at-home use, Alzheimer's agitation, acute stress reactions, and opioid withdrawal. Through its OnkosXcel Therapeutics subsidiary, the company is developing BXCL701, an innate immune activator for aggressive cancers. The company's proprietary NovareAI platform enables AI-driven drug re-innovation by identifying new indications for existing drugs and clinically evaluated compounds.

Product and service5 records
1IGALMI (dexmedetomidine) sublingual film
CategoryCommercial neuroscience pharmaceutical product
Description

FDA-approved sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I/II disorder in adults. Self-administered under healthcare provider supervision. Commercial product generating net revenue of $0.642 million in FY2025.

2BXCL501 (investigational dexmedetomidine sublingual film)
CategoryPipeline neuroscience pharmaceutical product
Description

Proprietary orally dissolving film formulation of dexmedetomidine being evaluated for agitation associated with dementia due to probable Alzheimer's disease, bipolar disorder/schizophrenia in the at-home setting, acute stress reactions, and opioid withdrawal symptoms. Has demonstrated over 30% reduction in opioid withdrawal scores versus placebo and significantly lower orthostatic hypotension rates (18%) versus lofexidine (50%).

3BXCL701
CategoryPipeline immuno-oncology pharmaceutical product
Description

Investigational oral innate immune activator developed to render 'cold' tumors 'hot,' making them more detectable by the adaptive immune system and potentially synergistic with checkpoint inhibitors. Being developed for metastatic castration-resistant prostate cancer (mCRPC) including small cell neuroendocrine carcinoma (SCNC) and adenocarcinoma phenotypes, pancreatic cancer, and other solid tumors.

4BXCL502
CategoryPipeline neuroscience pharmaceutical product
Description

Early-stage pipeline candidate being developed for the treatment of chronic agitation in dementia.

5BXCL503
CategoryPipeline neuroscience pharmaceutical product
Description

Early-stage pipeline candidate being developed for the treatment of apathy in dementia.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-15
Description

Engaged as financial advisor to explore strategic options for IGALMI franchise, including potential outright sale, merger, collaboration, or licensing agreements. The FDA decision on November 14, 2026 represents a critical binary event for potential transactions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-10
Description

Phase 2a trial of BXCL501 for acute stress reactions funded by U.S. Department of War, led by UNC Institute for Trauma Recovery. Trial evaluates drug's potential to reduce symptom severity and prevent progression to chronic neuropsychiatric symptoms following trauma.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial collaboration for BXCL501, including Phase 2 trial for opioid withdrawal symptoms in adults with opioid use disorder undergoing methadone taper.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial collaboration for BXCL501 neuroscience programs.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioXcel Therapeutics

Clinical-stage biopharmaceutical (neuroscience and immuno-oncology)bioxceltherapeutics.com

BioXcel Therapeutics is a clinical-stage biopharmaceutical company using its proprietary NovareAI platform to re-innovate existing drugs, commercializing IGALMI for acute agitation in schizophrenia/bipolar disorder and developing pipeline candidates BXCL501 (multiple neuroscience indications) and BXCL701 (immuno-oncology).

What BioXcel Therapeutics does

BioXcel Therapeutics is a clinical-stage biopharmaceutical company that applies its proprietary NovareAI platform — a composite of machine learning and big data analytics — to identify new therapeutic indications for existing approved drugs and clinically evaluated candidates, focusing on neuroscience and immuno-oncology. The company's lead commercial asset is IGALMI (BXCL501), a proprietary sublingual film formulation of dexmedetomidine that received FDA approval in April 2022 for the acute treatment of agitation associated with schizophrenia and bipolar I or II disorder in adults, distributed as a prescription pharmaceutical through healthcare providers under direct supervision.

The pipeline is built around BXCL501 extensions into adjacent indications (at-home use of IGALMI under FDA review with a November 14, 2026 decision target, agitation in Alzheimer's dementia with Breakthrough Therapy designation, opioid withdrawal with positive Phase 2 data, and Department of War-funded acute stress trials) plus BXCL701, an oral innate immune activator housed in the OnkosXcel Therapeutics subsidiary for aggressive cancers including metastatic castration-resistant prostate cancer and pancreatic cancer. The company also lists early-stage candidates BXCL502 (chronic dementia agitation) and BXCL503 (dementia apathy).

BioXcel generates revenue solely from IGALMI product sales, which declined sharply from $2.266 million in FY2024 to $0.642 million in FY2025 as the company pivoted resources toward an at-home launch and FDA submission. The business model combines product commercialization with repeated dilutive registered direct equity offerings; capital has also been raised through a $260 million strategic financing agreement with Oaktree Capital Management and Qatar Investment Authority. The company has engaged MTS Health Partners to explore strategic options including a potential sale, merger, collaboration, or licensing for the IGALMI franchise. BioXcel is headquartered in New Haven, Connecticut, trades on NASDAQ under ticker BTAI, and operates as a Delaware-incorporated C-corporation.

BioXcel Therapeutics firmographics

Firmographics
Name
BioXcel Therapeutics
Legal name
BioXcel Therapeutics, Inc.
Website
https://bioxceltherapeutics.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
BioXcel Therapeutics is a clinical-stage biopharmaceutical company using its proprietary NovareAI platform to re-innovate existing drugs, commercializing IGALMI for acute agitation in schizophrenia/bipolar disorder and developing pipeline candidates BXCL501 (multiple neuroscience indications) and BXCL701 (immuno-oncology).
Ownership category
akta.pro rank

BioXcel Therapeutics industry classification

Industry
Product category
Clinical-stage biopharmaceutical (neuroscience and immuno-oncology)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI-driven drug discovery
  • Neuroscience therapeutics
  • Immuno-oncology treatments
  • Sublingual pharmaceutical films
  • Clinical-stage biopharmaceutical

Where BioXcel Therapeutics is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioXcel Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. IGALMI Product Sales: BioXcel Therapeutics generates revenue from commercial sales of IGALMI (dexmedetomidine sublingual film), FDA-approved for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company reports declining revenue as focus shifts to at-home launch preparations.
  2. Strategic Financing: The company has raised capital through registered direct offerings of common stock and warrants, and strategic financing agreements with institutional investors including credit facilities and revenue interest financing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

BioXcel Therapeutics product offering

Product offering

Core offering

BioXcel Therapeutics develops and commercializes AI-enabled pharmaceutical products in neuroscience and immuno-oncology. Its commercial product is IGALMI, a sublingual dexmedetomidine film FDA-approved for acute agitation in schizophrenia and bipolar I/II disorder. The company also develops pipeline candidates including BXCL501 (additional agitation, opioid withdrawal, and acute stress indications), BXCL701 (immuno-oncology), BXCL502, and BXCL503, leveraging its proprietary NovareAI platform for drug re-innovation.

Product overview

BioXcel Therapeutics is a clinical-stage biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience and immuno-oncology. The company's commercial product is IGALMI™ (dexmedetomidine sublingual film), FDA-approved for acute treatment of agitation associated with schizophrenia or bipolar disorder. Its pipeline includes BXCL501, the same formulation in development for at-home use, Alzheimer's agitation, acute stress reactions, and opioid withdrawal. Through its OnkosXcel Therapeutics subsidiary, the company is developing BXCL701, an innate immune activator for aggressive cancers. The company's proprietary NovareAI platform enables AI-driven drug re-innovation by identifying new indications for existing drugs and clinically evaluated compounds.

Differentiator

Problem solved

Functional benefit

Brands

  • IGALMI: FDA-approved dexmedetomidine sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
  • NovareAI

Products and services

  • IGALMI (dexmedetomidine) sublingual film FDA-approved sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I/II disorder in adults. Self-administered under healthcare provider supervision. Commercial product generating net revenue of $0.642 million in FY2025.
  • BXCL501 (investigational dexmedetomidine sublingual film) Proprietary orally dissolving film formulation of dexmedetomidine being evaluated for agitation associated with dementia due to probable Alzheimer's disease, bipolar disorder/schizophrenia in the at-home setting, acute stress reactions, and opioid withdrawal symptoms. Has demonstrated over 30% reduction in opioid withdrawal scores versus placebo and significantly lower orthostatic hypotension rates (18%) versus lofexidine (50%).
  • BXCL701 Investigational oral innate immune activator developed to render 'cold' tumors 'hot,' making them more detectable by the adaptive immune system and potentially synergistic with checkpoint inhibitors. Being developed for metastatic castration-resistant prostate cancer (mCRPC) including small cell neuroendocrine carcinoma (SCNC) and adenocarcinoma phenotypes, pancreatic cancer, and other solid tumors.
  • BXCL502 Early-stage pipeline candidate being developed for the treatment of chronic agitation in dementia.
  • BXCL503 Early-stage pipeline candidate being developed for the treatment of apathy in dementia.

Quantifiable outcome

  • Phase 3 SERENITY At-Home trial met primary safety objective; BXCL501 reduced agitation compared to placebo across all baseline severity levels
  • +2 more outcomes

Companies that use BioXcel Therapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

BioXcel Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

BioXcel Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • MTS Health PartnersflagshipStrategic or Co-development Partner · 15 May 2026Engaged as financial advisor to explore strategic options for IGALMI franchise, including potential outright sale, merger, collaboration, or licensing agreements. The FDA decision on November 14, 2026 represents a critical binary event for potential transactions.
  • University of North Carolina at Chapel HillcoreStrategic or Co-development Partner · 10 April 2026Phase 2a trial of BXCL501 for acute stress reactions funded by U.S. Department of War, led by UNC Institute for Trauma Recovery. Trial evaluates drug's potential to reduce symptom severity and prevent progression to chronic neuropsychiatric symptoms following trauma.
  • Columbia UniversitycoreStrategic or Co-development PartnerClinical trial collaboration for BXCL501, including Phase 2 trial for opioid withdrawal symptoms in adults with opioid use disorder undergoing methadone taper.
  • Yale University Medical SchoolminorStrategic or Co-development PartnerClinical trial collaboration for BXCL501 neuroscience programs.

Scale indicators12 records

Recent moves8 records

Expansion highlights7 records

BioXcel Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioXcel Therapeutics social profiles

Digital presence

BioXcel Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioXcel Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

BioXcel Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BioXcel Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioXcel Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioXcel Therapeutics

What does BioXcel Therapeutics do?

BioXcel Therapeutics develops and commercializes AI-enabled pharmaceutical products in neuroscience and immuno-oncology. Its commercial product is IGALMI, a sublingual dexmedetomidine film FDA-approved for acute agitation in schizophrenia and bipolar I/II disorder. The company also develops pipeline candidates including BXCL501 (additional agitation, opioid withdrawal, and acute stress indications), BXCL701 (immuno-oncology), BXCL502, and BXCL503, leveraging its proprietary NovareAI platform for drug re-innovation.

Is BioXcel Therapeutics a public or private company?

BioXcel Therapeutics is a public company. It is classified as public and is currently operating.

When was BioXcel Therapeutics founded?

BioXcel Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is BioXcel Therapeutics based?

BioXcel Therapeutics is headquartered in New Haven, United States, in the North America region.

How does BioXcel Therapeutics make money?

Two revenue lines are on record. IGALMI Product Sales are the primary driver. The others are strategic Financing.

Does BioXcel Therapeutics have an API?

No public API is recorded for BioXcel Therapeutics.

What industry is BioXcel Therapeutics in?

BioXcel Therapeutics's product category is Clinical-stage biopharmaceutical (neuroscience and immuno-oncology). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Hartford Business JournalNew Haven biotech BioXcel prepares to shut down after $57.5M drug asset saleBioXcel Therapeutics is winding down after selling its main drug assets to Teva for $57.5 million and terminating four top executives. The sale includes rights to Igalmi, with up to $67.5 million tied to FDA approval and future sales. The company will change its name to BX Liquidation Inc. this month.InvestorshangoutDid anyone else notice this? On - CYDY CytoDyn IncA poster presented by Dr. Benjamin A. Weinberg at ESMO includes institutional disclosures for a research grant from Ipsen and trial chair roles for BioXcel Therapeutics and Merck. The author also references a prior comment on ctDNA and chemotherapy, and maintains a bullish stance on CYDY.In VivoDeal Watch: Teva Gets BioXcel Neuropsychiatric Assets In Bankruptcy ProceedingTeva announced on Oct. 27 that it has completed acquisition of BXCL501, potentially the first treatment for at-home administration. The deal is part of Teva's bankruptcy proceeding.The future of tradingTeva Acquires Worldwide Rights to BXCL501 From BioXcel TherapeuticsTeva completed its acquisition of BioXcel Therapeutics assets, including worldwide rights to investigational BXCL501 for at-home treatment of acute agitation in schizophrenia or bipolar disorder. FDA review covers this indication, and approval would make BXCL501 the first FDA-approved at-home treatment for the condition, expanding Teva's late-stage neuroscience pipeline.Defense WorldBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Sees Large Increase in Short InterestShort interest in BioXcel Therapeutics rose 84.8% to 6.12 million shares as of August 31. The company reported a Q2 loss of $0.49 per share, missing the $0.44 consensus, and revenue of $0.18 million versus $0.48 million estimated. Analysts have an average "Hold" rating with a $11 target.YahooTeva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?Teva Pharmaceuticals International agreed to bid up to $125 million in cash plus assumed liabilities for BioXcel Therapeutics' assets, including IGALMI. The bid includes a fixed $57.5 million closing payment and up to $67.5 million contingent, with a pending FDA PDUFA date of November 14, 2026. A competing bidder could submit a superior offer, and court approval is required.YahooTeva Seeks to Boost Neuroscience Portfolio With BioXcel Asset BidTeva Pharmaceutical announced a bid to acquire certain BioXcel Therapeutics assets, including the approved Igalmi dexmedetomidine sublingual film and the investigational BXCL501. Teva would pay $57.5 million upfront, with up to $67.5 million in contingent payments, and serves as stalking horse in a court-supervised auction. The deal would give Teva worldwide rights to the assets, subject to bankruptcy court approval.YahooTeva Pharmaceuticals to acquire BioXcel assets for up to $125mTeva Pharmaceuticals bid to acquire BioXcel Therapeutics' neuroscience assets for up to $125m, including Igalmi and BXCL501. The upfront consideration is $57.5m, with up to $67.5m in contingent payments tied to FDA approval and sales milestones. The deal is part of BioXcel's Chapter 11 court-supervised sale.YahooTeva Pharmaceuticals to acquire BioXcel assets for up to $125mTeva Pharmaceuticals has bid to acquire BioXcel Therapeutics' neuroscience assets for up to $125m, including Igalmi and BXCL501. The deal includes $57.5m upfront and up to $67.5m contingent on FDA approval and sales milestones. Teva is the stalking horse bidder in the court-supervised sale.Pharmaceutical TechnologyTeva Pharmaceuticals to acquire BioXcel assets for up to $125mTeva Pharmaceuticals bid $125m to acquire BioXcel Therapeutics' neuroscience assets, including Igalmi and BXCL501, in a court-supervised sale. The deal includes $57.5m upfront and up to $67.5m contingent on FDA approval and sales milestones. Teva is the stalking horse bidder in the auction process.